Monday – Friday 9 AM – 6 PM
855-KET-WELL 855-538-9355
NPR Highlights Ketamine’s Relief for Mending Broken Bridges in Brain NPR recently ran an article by John Hamilton titled, “Ketamine May Relieve Depression By Repairing Damaged Brain Circuits,” highlighting ketamine as a treatment option for depression as it repairs damaged brain circuits. This article is a great overview of where research currently stands with ketamine.…
DetailsCEO Update – April 2019 The month of March was one of KWC’s busiest months with record-breaking volumes in our clinics. We also successfully transitioned our corporate staff out of our Mesa clinical building into their own administrative space. Even with over 4,000 square feet and seven treatment rooms, we were getting crowded with the…
DetailsA closer look at Spravato/Esketamine. This episode focuses on the definition of Treatment Resistant Depression and looks at whether patients must be prescribed to an antidepressant while using Spravato. Additionally, what does one do about co-occurring conditions such as anxiety, suicidal ideation, ocd, etc?
DetailsKWC featured on Fox News 10 Discussing Spravato (esketamine) We had a great time discussing the latest news about the FDA’s recommended approval of Spravato (esketamine) for adults with treatment resistant depression with FOX News 10. Physician Dr. Mark Murphy sat down with Fox News 10 correspondent Nicole Garcia, to discuss what we do at KWC…
DetailsOne thing that raised the eyebrows of everybody on the clinical team here at KWC relates to the recommended dosing of Spravato. On this episode, we discuss what the recommended dosing is during the stabilization and maintenance treatment phases. Is the dosing variable from patient to patient or fixed? What are the implications of utilizing a non-variable prescription for dosing?
DetailsThis episode focuses on the cost of Spravato to the provide, end user, and insurer. What are the preliminary cost estimates for Spravato (wholesale)? Can we estimate the cost to the patient? Will insurance cover the drug? How will the treatment schedule effect the cost?
DetailsCEO Update – March 2019 THE GREATEST BREAKTHROUGH IN 30 YEARS FOR THE TREATMENT OF TREATMENT RESISTANT DEPRESSION IS SPRAVATO / ESKETAMINE! Is it really? Or are they just confirming what we have known for the last eight years? Yes, finally Johnson and Johnson has successfully received FDA approval to provide the medical community…
DetailsThis episode focuses on how Spravato is administered. Is intranasal delivery effective? What type of clinical environments can provide Spravato to patients? What duration of time will patients have to commit to treatment?
Details
